Please login to the form below

Not currently logged in
Email:
Password:

Cellerant appoints William Reed as VP clinical development

Will lead development of stem cell-based treatments for blood conditions and cancer

US biotech Cellerant Therapeutics has named Dr William Reed as VP, clinical development.

Dr Reed joins from Cerus Corporation and will lead the development of Cellerant's stem cell-based cellular and antibody therapies for blood disorders and cancer.

He has previous experience in treatments for blood conditions, spending time as director, clinical research and medical affairs at Cerus, where he worked on a programme for sickle cell disease.

Dr Reed was also an investigator at Blood Systems Research Institute in San Francisco and a medical director of the Human Islet and Cellular Transplantation Facility at University of California, San Francisco (UCSF).

Ram Mandalam, president and CEO of Cellerant, said:"His extensive experience in paediatric haematology/oncology and transfusion medicine will significantly benefit Cellerant in the development of CLT-008 for cord blood transplantation, leukaemia and acute radiation syndrome applications and the future clinical development of our cancer stem cell programme.”

15th February 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Redline Strategic

We are a healthcare consultancy, specialising in people and experiences. Using innovative research methods to capture the thoughts of real...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics